Monitor for commercial partnership announcements or distribution agreements in China, which would signal near-term revenue potential. The approval removes a key regulatory barrier, but execution risk remains high given the company's tiny market cap and need for commercial infrastructure in China.
Price Chart
Executive Summary
IceCure Medical received NMPA approval to market its ProSense cryoablation system in China as a Class III medical device. This regulatory milestone opens a large market for the company's flagship product, which is already approved in the US, Europe, and other Asian markets. For a $7M market cap company, this represents a significant expansion opportunity, though no financial terms or revenue projections were disclosed.
Key Facts
- Received NMPA approval for ProSense system and associated cryoprobes as a Class III medical device in China
- Approval enables marketing of ProSense in China in accordance with approved registration
- ProSense is IceCure's flagship cryoablation system for minimally invasive tumor destruction
- Company already markets ProSense in the US, Europe, and Asia for cleared indications
Financial Impact
No financial terms or market size disclosed. Opens Chinese market for ProSense system, but commercial ramp timeline and revenue contribution are unknown.
Risk Factors
- No disclosed revenue guidance or market size estimates for China opportunity
- Commercial execution risk in a complex regulatory and reimbursement environment
- Company has limited cash resources ($7M market cap) to fund China market entry without additional capital
- Competition from established cryoablation and ablation players in China
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-098595 |
| Document: ea030509601ex99-1.htm | 0001213900-26-098595 |
| Document: 0001213900-26-098595-index-headers.html | 0001213900-26-098595 |
| Document: 0001213900-26-098595-index.html | 0001213900-26-098595 |
| Document: 0001213900-26-098595.txt | 0001213900-26-098595 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $1.10 | awaiting T+60 | — | $1.03 (−6.36%) |
Oct 5, 2026 21d ago | 6-K | $1.27 | awaiting T+60 | — | $1.03 (−18.90%) |
Oct 5, 2026 21d ago | 6-K | $1.54 | awaiting T+60 | — | $1.03 (+33.12%) |
Sep 10, 2026 6w ago | 6-K | $2.14 | awaiting T+60 | — | $1.03 (−51.87%) |
Aug 24, 2026 9w ago | 6-K | $2.27 | awaiting T+60 | — | $1.03 (−54.63%) |
Aug 19, 2026 9w ago | EFFECT | $2.52 | awaiting T+60 | — | $1.03 (+59.13%) |
Aug 14, 2026 10w ago | 6-K | $2.82 | awaiting T+60 | — | $1.03 (−63.48%) |
Aug 12, 2026 10w ago | 6-K | $3.11 | awaiting T+60 | — | $1.03 (−66.83%) |
Jul 6, 2026 16w ago | EFFECT | $4.61 $1.59 | ▲ +65.51% | ▲ +67.23% | $1.03 (+77.66%) |
Jun 26, 2026 17w ago | 6-K | $5.26 $1.95 | ▲ +62.93% | ▲ +67.31% | $1.03 (+80.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers